A new tailored treatment for chronic graft-versus-host disease (chronic GVHD) has won UK approval for the first time, it has been announced.
The treatment is expected to benefit a small number of patients who do not respond to standard treatment....
3 months ago
A trial of a ‘third generation’ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown good results for relapsed or refractory B-Cell non-Hodgkin’s lymphomas, researchers have reported at the Annual Meeting of the American Society of H...
4 months ago
